Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

This paper summarizes the proceedings of an NIAID-sponsored workshop on statistical issues for HIV surrogate endpoints. The workshop brought together statisticians and clinicians in an attempt to shed light on some unresolved issues in the use of HIV laboratory markers (such as HIV RNA and CD4+ cell counts) in the design and analysis of clinical studies and in patient management. Utilizing a debate format, the workshop explored a series of specific questions dealing with the relationship between markers and clinical endpoints, and the choice of endpoints and methods of analysis in clinical studies. This paper provides the position statements from the two debaters on each issue. Consensus conclusions, based on the presentations and discussion, are outlined. While not providing final answers, we hope that these discussions have helped clarify a number of issues, and will stimulate further consideration of some of the highlighted problems. These issues will be critical in the proper assessment and use of future therapies for HIV disease.

[1]  J. Montaner,et al.  Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. , 1996, The Journal of infectious diseases.

[2]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[3]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[4]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[5]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[6]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[7]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[8]  P. Rosenbaum.  The Consequences of Adjustment for a Concomitant Variable that Has Been Affected by the Treatment , 1984 .

[9]  R. Detels,et al.  Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[10]  J O'Quigley,et al.  Predictive capability of proportional hazards regression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Rupert G. Miller.  Simultaneous Statistical Inference , 1966 .

[12]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[13]  J. Chmiel,et al.  Dependence of the hazard of AIDS on markers , 1997, AIDS.

[14]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[15]  J. Ioannidis,et al.  Predictive value of viral load measurements in asymptomatic untreated HIV‐1 infection: a mathematical model , 1996, AIDS.

[16]  J. Bartlett,et al.  HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. , 1996, AIDS.

[17]  J. Ioannidis,et al.  Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection. , 1996, American journal of epidemiology.

[18]  E. De Clercq,et al.  Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  J M Taylor,et al.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. , 1989, Journal of acquired immune deficiency syndromes.

[20]  D. Ho,et al.  Viral Counts Count in HIV Infection , 1996, Science.

[21]  T. Fleming,et al.  Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.

[22]  A. Phillips,et al.  Factors affecting survival in patients with the acquired immunodeficiency syndrome. , 1996, AIDS.

[23]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[24]  D. Lin,et al.  Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. , 1993, Statistics in medicine.

[25]  C. Meinert.  Clinical Trials: Design, Conduct, and Analysis , 1986 .

[26]  J. Neaton,et al.  CD4+ T lymphocyte counts and patterns of mortality among patients infected with human immunodeficiency virus who were enrolled in community programs for clinical research on AIDS. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  E. Emini.  Resistance to anti-human immunodeficiency virus therapeutic agents. , 1995, Advances in experimental medicine and biology.

[28]  S. Yusuf,et al.  Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. , 1990, Statistics in medicine.

[29]  H S Sacks,et al.  The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. , 1997, Controlled clinical trials.

[30]  J. Malone,et al.  Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. , 1990, Journal of acquired immune deficiency syndromes.

[31]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[32]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[33]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[34]  S. Kwok,et al.  A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity , 1997, Journal of clinical microbiology.

[35]  J M Taylor,et al.  Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. Multicenter AIDS Cohort Study. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[36]  T R Fleming,et al.  Surrogate markers in AIDS and cancer trials. , 1994, Statistics in medicine.

[37]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .

[38]  Beat Kleiner,et al.  Graphical Methods for Data Analysis , 1983 .

[39]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.

[40]  Thomas R. Fleming,et al.  Surrogate Endpoints in Clinical Trials , 1996 .

[41]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[42]  D. Katzenstein,et al.  HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. , 1994, Journal of acquired immune deficiency syndromes.

[43]  John M. Chambers,et al.  Graphical Methods for Data Analysis , 1983 .

[44]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[45]  D. Katzenstein,et al.  Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. , 1996, The Journal of infectious diseases.

[46]  Jeremy MG Taylor,et al.  Models for residual time to AIDS , 1996, Lifetime data analysis.

[47]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[48]  J. Sunyer,et al.  Comparison of semiparametric and parametric survival models for the analysis of bronchial responsiveness. , 1996, American Journal of Respiratory and Critical Care Medicine.

[49]  Robert W. Coombs,et al.  Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients , 1997 .

[50]  M. Wulfsohn,et al.  Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .

[51]  Douglas Richman,et al.  Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies , 1996, Annals of Internal Medicine.

[52]  J. Kahn,et al.  Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .

[53]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[54]  W. Guerra.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .